Table 3.
Pharmacokinetic parameters of peginterferon α-2b following once-weekly subcutaneous dosing (n = 20)
| Week | Dose (μg/kg) | Arithmetic mean (%CV) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| AUCtau (pg h/mL) | C max (pg/mL) | C avg (pg/mL) | C min (pg/mL) | T max (h)a | CL/F (l/h kg) | t 1/2 (h) | R b | ||
| 1 | 6 | 324,000 (38) | 3,980 (44) | 1,930 (38) | NA | 24 (24–72) | 0.0186 (50)c | 46 (24)c | NA |
| 8 | 6 | 462,000 (35) | 5,070 (51) | 2,750 (35) | 1,300 (56) | 24 (24–72) | 0.0152 (48) | 51 (18)d | 1.69 (64) |
| 12 | 3 | 235,000 (24) | 2,620 (33) | 1,400 (24) | 626 (43)d | 24 (24–48) | 0.0135 (25) | 43 (19) | NA |
AUCtau, area under the concentration–time curve during the dosing interval (168 h); C avg, average concentration within dosing interval; C max, maximal serum concentration; C min, minimum serum concentration; CL/F, apparent clearance; %CV, coefficient of variation expressed as a percentage; NA, not available; R, accumulation factor; t 1/2, terminal half-life; T max, observed time to achieve C max
aMedian (range)
bAccumulation factor R = AUCtau peginterferon α-2b at week 8/AUCtau peginterferon α-2b at week 1
c n = 14; CL/F cannot be reported for some patients because t 1/2 cannot be determined accurately
d n = 19; no concentration data were available for one patient at week 12